Dr. Anthony R. Mato, MD

Dr. Mato practices at Arnot Ogden Medical Center in Elmira, New York, part of Centralus Health.

Dr. Mato's NPI, 1053473983, was assigned on December 15, 2006. Dr. Mato holds Pennsylvania license MD424888.

Dr. Mato's primary practice is Arnot Ogden Medical Center, at 600 Roe Avenue, Elmira, NY 14905 in Chemung County. The practice phone is (607) 737-4100.

Dr. Mato's primary practice is Arnot Ogden Medical Center in Elmira, New York, part of Centralus Health. Dr. Mato is also affiliated with Cayuga Medical Center. The medical group on file is Arnot Ogden Medical Center. Dmand AI also links Dr. Mato to 2 more hospitals, 5 medical groups and 2 group practices and clinics, each named with a free account. Dr. Mato's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mato practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mato's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Mato is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Mato's licenses on file in 2 states: Pennsylvania and New Jersey.

CMS data shows 563 Medicare services from Dr. Mato across 8 procedure codes in 2024, for 211 Medicare patients. Medicare paid $47,353 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 211 Medicare patients who saw Dr. Mato in 2024. The largest group is 65 to 74, with 79 patients. 74% of them have high blood pressure, and 66% have high cholesterol. 26% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mato's median patient age at 70, with 59% women.

In 2024, Dr. Mato wrote 475 Medicare Part D claims for 122 patients. 77% of them were for generic drugs. CMS names the drug for 250 of them, across 10 drugs with 11 or more claims each, at $562,739 in total drug cost. In 2023, CMS named 102 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Mato for performance year 2024, reported through an alternative payment model (APM). Dr. Mato accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mato as offering telehealth.

Dmand AI links Dr. Mato to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell and Leukemia, B-Cell. Open Payments lists research payments to Dr. Mato that name 2 trials.

CMS Open Payments shows 424 general payments to Dr. Mato from 29 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 91% of the total. AstraZeneca Pharmaceuticals LP paid the most, $691,694. It also lists 36 research payments totaling $36,419 from 2016 to 2021, naming 2 clinical trials.